7th Annual Immuno-Oncology Summit 2019
-第7屆癌症免疫療法高峰會-
日期:2019年8月5-9日
地點:美國馬薩諸塞州波士頓,Westin Boston Waterfront
Choose your language
Chinese
Japanese
Korean
English

目錄下載 (PDF) 目錄下載(PDF)

以癌症免疫為主題的最大型學會

這場聚焦於癌症免疫的重要盛會,將會有超過675人的製藥產業意見領袖聚集。在研討會期間,將會網羅相關領域的12個分科會為大家帶來最新的研究成果,除此之外,還能夠跟來自世界各地出席的業者建立長期合作關係,這之中不乏主要企業的幹部。另外還能獲得讓次世代免疫療法的開發專案有所斬獲的實用對策。

主要演講者

Litao Zhang, Vice President, Leads Discovery and Optimization, Bristol-Myers Squibb

Adya_Neeraj

Neeraj Adya, PhD, Director, Pharmacodiagnostics, Bristol-Myers Squibb

John Desjarlais, PhD, Senior Vice President, Research, CSO, Xencor

Pamela Carroll, PhD, Senior Vice President, Immuno-Oncology, Genocea

Jianda Yuan, MD, PhD, Senior Director, Translational Oncology, Merck

Andrew Allen, President and CEO, Gritstone Oncology

Michael Woo, Head, Immuno-Oncology, Business Development, Novartis

Catherine Sabatos-Peyton, Director, Exploratory Immuno-Oncology, Novartis

Cokey Nguyen, Senior Director, Oncology R&D, Pfizer

Jon Wigginton, Senior Vice President & CMO, MacroGenics

Adrian Bot, Vice President, Translational Sciences, Kite, a Gilead Company

Tara Arvedson, PhD, Director, Oncology Research, Amgen

Philip Arlen, President & CEO, Precision Biologics

Arthur Krieg, Founder & CSO, Checkmate Pharmaceuticals

Kevin R. Webster, Senior Vice President, eFFECTOR Therapeutics

Stephen Doberstein, Chief Research and Development Officer, Nektar Therapeutics

David Kirn, Co-Founder & Executive Chairman, IGNITE Immunotherapy

Kathryn McCabe, Senior Director, Emerging Technology and Innovation, Eli Lilly

Scott M. DeWire, Global Head, Business Development and Licensing, Boehringer Ingelheim

Griffith_Melinda

Melinda Griffith, JD, Vice President, Strategic Alliances; Chief Legal Counsel, Parker Institute for Cancer Immunotherapy

Caron Jacobson, MD, Medical Director, Immune Effector Cell Therapy Program, Dana Farber Cancer Institute

Howard Kaufman, PhD, CMO, Replimune

Paola Grandi, PhD, CSO, Cold Genesys

Preet M. Chaudhary, MD, PhD, Chief of Hematology, University of Southern California Keck School of Medicine

John Quackenbush, PhD, Chair, Department of Biostatistics, Harvard T.H. Chan School of Public Health


Why attend CHI’s Immuno-Oncology Summit?


NETWORK
with 675+ IO thought leaders from 28 countries and 400 companies

LEARN
the latest developments in immuno-oncology from 175+ scientific presentations and 40+ posters

CUSTOMIZE
your comprehensive 5-day program by selecting from 12-tracks, 2 training seminars, 1 partnering forum and 1 course

CONNECT
at the industry’s leading Immuno-Oncology meeting, with 72% of delegates from biotech and pharma

COLLABORATE
and build lasting business relationships with IO decision-makers: 46% of delegates are executive/director level

INNOVATE
your projects with technology solutions from 40+ exhibitors and 20+ technical presentations

BRAINSTORM
actionable solutions at the expertly-facilitated roundtable discussions

FOCUS
on your agenda by track hopping between concurrent tracks

SHOWCASE
your research by presenting a scientific poster


推薦參加Immuno-Oncology Summit的原因


建構人脈
來自全世界28個國家將近400家企業,在癌症免疫療法領域上佔有一席之地的意見領袖高達675人以上,這些人將在此齊聚一堂。

吸收知識
能在此經由175件以上的研究發表以及40件以上的海報發表,學習癌症免疫療法的最新動態。

豐富的集會
長達5日的高峰會議裡,您可從以下會議選擇其一參加:12個分科會、2個研修講座、投資提攜論壇、4個Showcase。

為數眾多的相關人士
72%的出席者是生技產業及製藥廠的職員,在以癌症免疫療法為主題的相關業界裡是重要活動。

建立合作關係
將近有46%的出席者是癌症免疫療法的相關組織的董事或是總監等級的幹部,有機會跟這些幹部建立事業上的長期關係。

革新的技術
預計將會有40組以上的參展者出席這個展覽,並且會有20個以上的簡報,可以找到可運用在開發專案上的技術對策。

腦力激盪
專家擔任主持人的團體討論將會在此進行,您可學習到實用性的知識運用在解決問題上。

尋找您感興趣的主題
您可在同時進行的分科會當中選擇您感興趣的主題集會。

海報發表
可以透過海報發表展示相關研究成果。

介紹新興企業

成為介紹新興企業的免疫療法投資提攜論壇,是被放入此學會議題的專案。在這個論壇裡,您能夠對癌症免疫療法的相關企業及投資公司的幹部,宣傳您的醫藥品、醫療機器、診斷方法及軟體。

 
免費電子郵件通知服務